GB201009222D0 - Improved cancer therapy based on tumour associated antigens derived from cyclin D1 - Google Patents

Improved cancer therapy based on tumour associated antigens derived from cyclin D1

Info

Publication number
GB201009222D0
GB201009222D0 GB201009222A GB201009222A GB201009222D0 GB 201009222 D0 GB201009222 D0 GB 201009222D0 GB 201009222 A GB201009222 A GB 201009222A GB 201009222 A GB201009222 A GB 201009222A GB 201009222 D0 GB201009222 D0 GB 201009222D0
Authority
GB
United Kingdom
Prior art keywords
cyclin
cancer therapy
associated antigens
therapy based
antigens derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201009222A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to GB201009222A priority Critical patent/GB201009222D0/en
Publication of GB201009222D0 publication Critical patent/GB201009222D0/en
Priority to AU2011260277A priority patent/AU2011260277B2/en
Priority to KR1020127034291A priority patent/KR20130089175A/ko
Priority to EP11722825.4A priority patent/EP2575850A1/en
Priority to EA201291195A priority patent/EA201291195A1/ru
Priority to BR112012030479A priority patent/BR112012030479A2/pt
Priority to US13/643,043 priority patent/US9023803B2/en
Priority to SG2012065918A priority patent/SG185353A1/en
Priority to CA2793601A priority patent/CA2793601A1/en
Priority to JP2013512926A priority patent/JP2013536157A/ja
Priority to MX2012013998A priority patent/MX2012013998A/es
Priority to CN2011800266565A priority patent/CN102971003A/zh
Priority to US13/150,785 priority patent/US9056069B2/en
Priority to PCT/EP2011/059121 priority patent/WO2011151403A1/en
Priority to MYPI2012700611A priority patent/MY162741A/en
Priority to PH1/2012/501898A priority patent/PH12012501898A1/en
Priority to UAA201210089A priority patent/UA110473C2/uk
Priority to NZ60167711A priority patent/NZ601677A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB201009222A 2010-06-02 2010-06-02 Improved cancer therapy based on tumour associated antigens derived from cyclin D1 Ceased GB201009222D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GB201009222A GB201009222D0 (en) 2010-06-02 2010-06-02 Improved cancer therapy based on tumour associated antigens derived from cyclin D1
NZ60167711A NZ601677A (en) 2010-06-02 2011-06-01 Improved cancer therapy based on tumor associated antigens derived from cyclin d1
CA2793601A CA2793601A1 (en) 2010-06-02 2011-06-01 Improved cancer therapy based on tumor associated antigens derived from cyclin d1
MX2012013998A MX2012013998A (es) 2010-06-02 2011-06-01 Tratamiento mejorado contra el cancer basado en antigenos asociados a tumor derivados de la ciclina d1.
EP11722825.4A EP2575850A1 (en) 2010-06-02 2011-06-01 Improved cancer therapy based on tumor associated antigens derived from cyclin d1
EA201291195A EA201291195A1 (ru) 2010-06-02 2011-06-01 Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
BR112012030479A BR112012030479A2 (pt) 2010-06-02 2011-06-01 terapia aprimorada de câncer baseada em antígenos associados a tumor derivados de ciclina d1
US13/643,043 US9023803B2 (en) 2010-06-02 2011-06-01 Cancer therapy based on tumor associated antigens derived from cyclin D1
SG2012065918A SG185353A1 (en) 2010-06-02 2011-06-01 Improved cancer therapy based on tumor associated antigens derived from cyclin d1
AU2011260277A AU2011260277B2 (en) 2010-06-02 2011-06-01 Improved cancer therapy based on tumor associated antigens derived from cyclin D1
JP2013512926A JP2013536157A (ja) 2010-06-02 2011-06-01 サイクリンｄ１由来腫瘍関連抗原に基づくがん治療法の改良
KR1020127034291A KR20130089175A (ko) 2010-06-02 2011-06-01 사이클린 d1에서 유래된 종양 관련 항원을 기반으로 한 향상된 암 치료요법
CN2011800266565A CN102971003A (zh) 2010-06-02 2011-06-01 基于细胞周期素d1衍生的肿瘤相关抗原的癌症改进疗法
US13/150,785 US9056069B2 (en) 2010-06-02 2011-06-01 Cancer therapy based on tumor associated antigens derived from cyclin D1
PCT/EP2011/059121 WO2011151403A1 (en) 2010-06-02 2011-06-01 Improved cancer therapy based on tumor associated antigens derived from cyclin d1
MYPI2012700611A MY162741A (en) 2010-06-02 2011-06-01 Improved cancer therapy based on tumor associated antigens derived from cyclin D1
PH1/2012/501898A PH12012501898A1 (en) 2010-06-02 2011-06-01 Improved cancer therapy based on tumor associated antigens derived from cyclin d1
UAA201210089A UA110473C2 (uk) 2010-06-02 2011-06-01 Спосіб лікування раку за допомогою пухлиноасоційованого антигену, отриманого із цикліну d1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201009222A GB201009222D0 (en) 2010-06-02 2010-06-02 Improved cancer therapy based on tumour associated antigens derived from cyclin D1

Publications (1)

Publication Number Publication Date
GB201009222D0 true GB201009222D0 (en) 2010-07-21

Family

ID=42471037

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201009222A Ceased GB201009222D0 (en) 2010-06-02 2010-06-02 Improved cancer therapy based on tumour associated antigens derived from cyclin D1

Country Status (17)

Country Link
US (2) US9023803B2 (cg-RX-API-DMAC7.html)
EP (1) EP2575850A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013536157A (cg-RX-API-DMAC7.html)
KR (1) KR20130089175A (cg-RX-API-DMAC7.html)
CN (1) CN102971003A (cg-RX-API-DMAC7.html)
AU (1) AU2011260277B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012030479A2 (cg-RX-API-DMAC7.html)
CA (1) CA2793601A1 (cg-RX-API-DMAC7.html)
EA (1) EA201291195A1 (cg-RX-API-DMAC7.html)
GB (1) GB201009222D0 (cg-RX-API-DMAC7.html)
MX (1) MX2012013998A (cg-RX-API-DMAC7.html)
MY (1) MY162741A (cg-RX-API-DMAC7.html)
NZ (1) NZ601677A (cg-RX-API-DMAC7.html)
PH (1) PH12012501898A1 (cg-RX-API-DMAC7.html)
SG (1) SG185353A1 (cg-RX-API-DMAC7.html)
UA (1) UA110473C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011151403A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
CN103848891B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Ccnd1自身抗体识别的抗原多肽
US10206985B2 (en) * 2013-02-05 2019-02-19 Nitto Denko Corporation WT1 peptide cancer vaccine composition for mucosal administration
CA2841016A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for transdermal administration
ES3009756T3 (en) 2013-08-05 2025-03-31 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors, such as lung cancer including nsclc
TWI777196B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（五）
CN104017051B (zh) * 2014-06-23 2016-08-17 深圳市华中生物药械有限公司 一种Cyclin D 蛋白抑制剂多肽及其应用
CR20200526A (es) 2015-06-19 2020-12-23 Immatics Biotechnologies Gmbh NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA Y MÉTODOS PARA CREAR SOPORTES PARA EL USO CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2018-0040)
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
HK1254866A1 (zh) 2015-06-25 2019-07-26 Immatics Biotechnologies Gmbh 用於骨髓瘤和其他癌症免疫治疗的新型细胞表位和细胞表位组合物
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
MA51531A (fr) * 2015-07-06 2020-11-11 Immatics Biotechnologies Gmbh Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
MY198087A (en) 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
CN114028549A (zh) 2016-02-19 2022-02-11 伊玛提克斯生物技术有限公司 用于nhl和其他癌症免疫治疗的新型肽和肽组合物
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
CN116375797A (zh) 2016-03-01 2023-07-04 伊玛提克斯生物技术有限公司 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
NZ754222A (en) 2016-12-08 2022-02-25 Immatics Biotechnologies Gmbh T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CN112553336B (zh) * 2020-12-17 2023-07-21 兰州大学 Snp在乳腺癌化疗耐药性检测领域的应用及其检测试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
DE10225144A1 (de) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2005035714A2 (en) 2003-08-26 2005-04-21 Board Of Regents, The University Of Texas System Vaccines for cancer, autoimmune disease and infections
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
PL1642905T3 (pl) 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
SI1806359T1 (sl) * 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se vežejo brez izjeme na molekule humanega levkocitnega antigena HLA razred II
ES2330013T3 (es) 2005-09-05 2009-12-03 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas.
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
UA103882C2 (uk) 2007-07-27 2013-12-10 Імматікс Біотекнолоджіс Гмбх Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина
EP3085707B1 (en) * 2007-11-01 2019-02-27 Mayo Foundation for Medical Education and Research Hla-dr binding peptides and their uses
ES2532896T5 (es) * 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
JP5883653B2 (ja) * 2009-03-10 2016-03-15 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗原提示細胞ターゲティング抗ウイルスワクチン
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1

Also Published As

Publication number Publication date
US9023803B2 (en) 2015-05-05
NZ601677A (en) 2015-01-30
JP2013536157A (ja) 2013-09-19
AU2011260277A1 (en) 2012-08-30
AU2011260277B2 (en) 2015-01-15
WO2011151403A1 (en) 2011-12-08
MX2012013998A (es) 2013-01-28
KR20130089175A (ko) 2013-08-09
BR112012030479A2 (pt) 2017-01-24
EA201291195A1 (ru) 2014-06-30
US9056069B2 (en) 2015-06-16
UA110473C2 (uk) 2016-01-12
MY162741A (en) 2017-07-15
PH12012501898A1 (en) 2019-07-10
US20130177525A1 (en) 2013-07-11
SG185353A1 (en) 2012-12-28
CA2793601A1 (en) 2011-12-08
EP2575850A1 (en) 2013-04-10
US20120027684A1 (en) 2012-02-02
CN102971003A (zh) 2013-03-13

Similar Documents

Publication Publication Date Title
GB201009222D0 (en) Improved cancer therapy based on tumour associated antigens derived from cyclin D1
IL279330A (en) Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer
IL276434A (en) Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer
MX2021008224A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
MX2022001105A (es) Anticuerpos anti tigit.
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
EP4364796A3 (en) Use of linagliptin in cardio- and renoprotective antidiabetic therapy
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
SI2852408T1 (sl) Kombinacijska terapija, ki vključuje protitelesa proti claudin 18.2 za zdravljenje raka
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
PH12014500973A1 (en) Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies
HK40126719A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014009245A3 (en) Novel drug target indentification methods
HK1182922A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin d1
UA65175U (en) Method of uranostaphyloplasty

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)